[Effects of gossypol and GnRHa on the prostaglandins contents of endometriotic cell and in situ].
In order to study a direct effect of some traditional and western medicine on the prostaglandins (PGs) of endometriosis, endometriotic cell and endometrial cell in situ were cultured in vitro. 6-keto-PGF1 alpha and thromboxane (TXB2) were measured in the above cells using the RIA from the superfusates. These PGs changes after gossypol acetate, progesterone, danazol and gonadotrophin releasing hormone agonist (GnRHa) treatment were studied. High PGs levels were observed in endometriotic cell, and higher in endometrial cell in situ of patients than in endometrial cell of healthy persons (P less than 0.01). After treatment with drug (but not GnRHa), the prostacyclin (PGI2) and TXB2 content were reduced in endometriotic cell, and the TXB2 contents were reduced in endometrial cell in situ (P less than 0.01). These results indicate that endometriotic cell and endometrial cell in situ can produce more PGI2 and TXB2--at least in vitro, which perhaps may provide an explanation for the puzzling clinical phenomenon of endometriosis. Gossypol acetate, progesterone and danazol inhibit PGI2 and TXB2 content in endometrial cell of patients with endometriosis. It is pertinent to ask whether these drugs can be used to improve endometriosis-associated infertility or dysmenorrhea as well.
Huang
H F
HF
Dept. of Obstetrics and Gynecology, Zhejiang Medical University, Hangzhou.
Wang
M
M
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism*; D000328:Adult; D004715:Endometriosis / Q000473:pathology*; D004717:Endometrium / Q000378:metabolism; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology*; D006072:Gossypol / Q000494:pharmacology*; D006801:Humans; D010386:Pelvic Neoplasms / Q000473:pathology*; D013929:Thromboxane B2 / Q000378:metabolism
D007987:Gonadotropin-Releasing Hormone; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D006072:Gossypol